Price

1W %

1M %

3M %

6M %

1Y %

YTD %

--

--

--

--

--

--

--

Simulations Plus, Inc.

NASDAQ

Market Cap.

913.31M

Avg. Volume

106.63K

AI Analyst

Streamlined AI Analyst

Hi I’m your personal financial assistant, click on one of the options below and I’ll help you analyze Simulations Plus, Inc.!

Still processing it, give me a bit more time...

Simulations Plus, Inc. News

Simulations Plus, Inc. Score

Overall Score

Growth

Value

Quality

Moment.

Momentum

Stability

HealthcareMedical - Healthcare Information Services
simulations-plus.com

About Simulations Plus, Inc.

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. It operates through four segments: Simulations Plus, Cognigen, DILIsym, and Lixoft. The company offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. It also provides products based on mechanistic and mathematical models, such as DILIsym, a quantitative systems pharmacology software; NAFLDsym; IPFsym; RENAsym; and MITOsym. In addition, the company provides Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as modeling and simulation products comprising MonolixSuite and PKPlus. Further, it provides population modeling and simulation contract research services; training and consulting services designed to accelerate pharmacometrics studies; and clinical-pharmacology-based consulting services in support of regulatory submissions. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.

Simulations Plus, Inc. Earnings & Revenue

Simulations Plus, Inc. Financials

Table Compare

Compare SLP metrics with:

   

Earnings & Growth

SLP

None

EPS (TTM) YoY Growth

--

--

Revenue (TTM) YoY Growth

--

--

 

Valuation (TTM)

SLP

None

Price/Earnings Ratio

--

--

Price/Sales Ratio

--

--

 

Profitability & Efficiency (TTM)

SLP

None

Net Profit Margin

--

--

Return on Equity

--

--

 

Financial Health (TTM)

SLP

None

Debt Ratio

--

--

Quick Ratio

--

--

 

Simulations Plus, Inc. Income

Simulations Plus, Inc. Balance Sheet

Simulations Plus, Inc. Cash Flow

Simulations Plus, Inc. Financials Over Time

Analysts Rating

Strong Buy

Buy

Hold

Sell

Strong Sell

Metrics Scores

MetricsScore
Discounted Cash FlowsBuy
Return on EquityBuy
Return on AssetsStrong Buy
Debt/Equity RatioNeutral
Price/Earnings RatioStrong Buy
Price/Book RatioStrong Buy

Price Targets


Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.

Simulations Plus, Inc. Dividends

Payment DateDividendFrequency
2024-05-060.06Quarterly
2024-02-050.06Quarterly
2023-11-060.06Quarterly
2023-08-070.06Quarterly
2023-05-010.06Quarterly

Historical Market Cap

Shares Outstanding

Simulations Plus, Inc. Executives

NameRole
Mr. Shawn M. O'ConnorChief Executive Officer
Mr. William FrederickChief Operating Officer, Chief Financial Officer & Secretary
Mr. John Anthony DiBella M.S.President of PBPK & Cheminformatics Solutions
Ms. Jill Fiedler-Kelly M.S.President of Clinical Pharmacology & Pharmacometrics Services
Dr. Brett A. Howell Ph.D.President of Quantitative Systems Pharmacology Solutions
NameRoleGenderDate of BirthPay
Mr. Shawn M. O'ConnorChief Executive OfficerMale1960847.56K
Mr. William FrederickChief Operating Officer, Chief Financial Officer & SecretaryMale1964443.12K
Mr. John Anthony DiBella M.S.President of PBPK & Cheminformatics SolutionsMale1980399.8K
Ms. Jill Fiedler-Kelly M.S.President of Clinical Pharmacology & Pharmacometrics ServicesFemale1969393.77K
Dr. Brett A. Howell Ph.D.President of Quantitative Systems Pharmacology Solutions1984321.67K

Simulations Plus, Inc. Insider Trades

Date1 Apr
NameWOLTOSZ WALTER S
RoleDirector, 10 percent owner
TransactionDisposed
TypeS-Sale
Shares19410
Date1 Apr
NameWOLTOSZ WALTER S
RoleDirector, 10 percent owner
TransactionDisposed
TypeS-Sale
Shares590
Date28 Mar
NameSzot Daniel
RoleChief Revenue Officer
TransactionAcquired
TypeA-Award
Shares30000
Date1 Mar
NameWOLTOSZ WALTER S
RoleDirector, 10 percent owner
TransactionDisposed
TypeS-Sale
Shares17600
Date1 Mar
NameWOLTOSZ WALTER S
RoleDirector, 10 percent owner
TransactionDisposed
TypeS-Sale
Shares2400
DateNameRoleTransactionTypeShares
1 AprWOLTOSZ WALTER SDirector, 10 percent ownerDisposedS-Sale19410
1 AprWOLTOSZ WALTER SDirector, 10 percent ownerDisposedS-Sale590
28 MarSzot DanielChief Revenue OfficerAcquiredA-Award30000
1 MarWOLTOSZ WALTER SDirector, 10 percent ownerDisposedS-Sale17600
1 MarWOLTOSZ WALTER SDirector, 10 percent ownerDisposedS-Sale2400

Discover More

Simulations Plus, Inc.

NASDAQ

Market Cap.

913.31M

Avg. Volume

106.63K

Price

1W %

1M %

3M %

6M %

1Y %

YTD %

--

--

--

--

--

--

--

Simulations Plus, Inc. News

Simulations Plus, Inc. Score

Overall Score

Growth

Value

Quality

Moment.

Momentum

Stability

Simulations Plus, Inc. Earnings & Revenue

Simulations Plus, Inc. Income

Simulations Plus, Inc. Balance Sheet

Simulations Plus, Inc. Cash Flow

Simulations Plus, Inc. Financials Over Time

Simulations Plus, Inc. Executives

NameRole
Mr. Shawn M. O'ConnorChief Executive Officer
Mr. William FrederickChief Operating Officer, Chief Financial Officer & Secretary
Mr. John Anthony DiBella M.S.President of PBPK & Cheminformatics Solutions
Ms. Jill Fiedler-Kelly M.S.President of Clinical Pharmacology & Pharmacometrics Services
Dr. Brett A. Howell Ph.D.President of Quantitative Systems Pharmacology Solutions
NameRoleGenderDate of BirthPay
Mr. Shawn M. O'ConnorChief Executive OfficerMale1960847.56K
Mr. William FrederickChief Operating Officer, Chief Financial Officer & SecretaryMale1964443.12K
Mr. John Anthony DiBella M.S.President of PBPK & Cheminformatics SolutionsMale1980399.8K
Ms. Jill Fiedler-Kelly M.S.President of Clinical Pharmacology & Pharmacometrics ServicesFemale1969393.77K
Dr. Brett A. Howell Ph.D.President of Quantitative Systems Pharmacology Solutions1984321.67K

Simulations Plus, Inc. Insider Trades

Date1 Apr
NameWOLTOSZ WALTER S
RoleDirector, 10 percent owner
TransactionDisposed
TypeS-Sale
Shares19410
Date1 Apr
NameWOLTOSZ WALTER S
RoleDirector, 10 percent owner
TransactionDisposed
TypeS-Sale
Shares590
Date28 Mar
NameSzot Daniel
RoleChief Revenue Officer
TransactionAcquired
TypeA-Award
Shares30000
Date1 Mar
NameWOLTOSZ WALTER S
RoleDirector, 10 percent owner
TransactionDisposed
TypeS-Sale
Shares17600
Date1 Mar
NameWOLTOSZ WALTER S
RoleDirector, 10 percent owner
TransactionDisposed
TypeS-Sale
Shares2400
DateNameRoleTransactionTypeShares
1 AprWOLTOSZ WALTER SDirector, 10 percent ownerDisposedS-Sale19410
1 AprWOLTOSZ WALTER SDirector, 10 percent ownerDisposedS-Sale590
28 MarSzot DanielChief Revenue OfficerAcquiredA-Award30000
1 MarWOLTOSZ WALTER SDirector, 10 percent ownerDisposedS-Sale17600
1 MarWOLTOSZ WALTER SDirector, 10 percent ownerDisposedS-Sale2400
HealthcareMedical - Healthcare Information Services
simulations-plus.com

About Simulations Plus, Inc.

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. It operates through four segments: Simulations Plus, Cognigen, DILIsym, and Lixoft. The company offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. It also provides products based on mechanistic and mathematical models, such as DILIsym, a quantitative systems pharmacology software; NAFLDsym; IPFsym; RENAsym; and MITOsym. In addition, the company provides Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as modeling and simulation products comprising MonolixSuite and PKPlus. Further, it provides population modeling and simulation contract research services; training and consulting services designed to accelerate pharmacometrics studies; and clinical-pharmacology-based consulting services in support of regulatory submissions. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.

AI Analyst

Streamlined AI Analyst

Hi I’m your personal financial assistant, click on one of the options below and I’ll help you analyze Simulations Plus, Inc.!

Still processing it, give me a bit more time...

Simulations Plus, Inc. Financials

Table Compare

Compare SLP metrics with:

   

Earnings & Growth

SLP

None

EPS (TTM) YoY Growth

--

--

Revenue (TTM) YoY Growth

--

--

 

Valuation (TTM)

SLP

None

Price/Earnings Ratio

--

--

Price/Sales Ratio

--

--

 

Profitability & Efficiency (TTM)

SLP

None

Net Profit Margin

--

--

Return on Equity

--

--

 

Financial Health (TTM)

SLP

None

Debt Ratio

--

--

Quick Ratio

--

--

 

Simulations Plus, Inc. Valuation

Project future cash flows and get the intrinsic value per share.

Start valuation modeling

Analysts Rating

Strong Buy

Buy

Hold

Sell

Strong Sell

Metrics Scores

MetricsScore
Discounted Cash FlowsBuy
Return on EquityBuy
Return on AssetsStrong Buy
Debt/Equity RatioNeutral
Price/Earnings RatioStrong Buy
Price/Book RatioStrong Buy

Price Targets


Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.

Simulations Plus, Inc. Dividends

Payment DateDividendFrequency
2024-05-060.06Quarterly
2024-02-050.06Quarterly
2023-11-060.06Quarterly
2023-08-070.06Quarterly
2023-05-010.06Quarterly

Historical Market Cap

Shares Outstanding

Discover More